A phase 2b study of IW-601 for inflammation and immunological disorders
Latest Information Update: 25 Dec 2025
At a glance
- Drugs IW 601 (Primary)
- Indications Immunological disorders; Inflammation
- Focus Therapeutic Use
Most Recent Events
- 25 Dec 2025 New trial record
- 11 Dec 2025 Accoridng to an ImmuneWalk Therapeutics media release, company plans a phase I trial for inflammation and immunological disorders in the first half of 2027.